First time published in a peer-reviewed journal: birtamimab is the only investigational drug that has shown a significant survival benefit in patients with Mayo Stage IV AL amyloidosis in a double-blind placebo-controlled clinical trial
A significant improvement in time to all-cause mortality at month 9 was observed with birtamimab versus placebo and remained consistent across all key baseline variables in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis
Birtamimab is currently being studied in the confirmatory Phase 3 clinical trial, AFFIRM-AL, in patients with Mayo Stage IV AL amyloidosis; topline data is expected in 2024